Stimus (darbepoetin alfa biosimilar) / Nanogen Biopharma - LARVOL DELTA

Prognostic factors and survival outcomes of urgent inpatient chemotherapy for relapsed/refractory lymphoma in the modern era (ASH 2025) - "Chemo regimens include methotrexate/cytarabine-based(n=25), conventional chemo (n=23), polatuzumab-based (n=18), gemcitabine-based (n=15) andbispecific/monoclonal antibody/antibody drug conjugate (n=15)...Prior ASCT (p=.024), low Hb (p=.035), ≥4 prior therapies (p=.046), no (peg)filgrastimuse (p=.016), and low GFR (p=.048) resulted in poor OS.On multivariate analysis, refractoriness to last regimen (hazard ratio [HR]OS=1.78 [95% CI:1.09-2.91; p=.02]; HRPFS=2.08; [1.31-3.30; p=.002]) and prior CAR-T (HROS=2.07; [1.10-3.89; p=.02]; HRPFS=2.60; [1.37-4.93; p=.003]) significantly impacted survival... Our analysis shows poor outcomes in RR lymphoma pts following urgent inpt chemotreatment with median OS<4 months. Impaired organ function and chemo-refractory disease werepredictive for survival and response to inpt chemo. In an era of rising healthcare costs, optimal ptselection is essential to maximize the clinical benefits of such interventions."

Biomarker • Clinical • B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Septic Shock • T Cell Non-Hodgkin Lymphoma

Duration of music listening in music-induced analgesia: a pilot randomized controlled trial. (PubMed, Complement Ther Med) - "Translating these findings to clinical care, it seems advisable for patients to listen to music for a sufficient amount of time (≥20minutes) to achieve effective MIA. Further research is needed to validate these results and determine the optimal "dosage" for MIA."

Journal • Pain

Chemical Characterization, Sensory Evaluation, and Biological Activity in Neuronal Cells of Essential Oils (Rose, Eucalyptus, Lemon, and Clove) Used for Olfactory Training. (PubMed, Molecules) - "We conducted a conjunct evaluation of the chemical composition, sensory profile, and bioactivity in cell models of commercial EOs of rose (EO1), eucalyptus (EO2), lemon (EO3), and clove (EO4) used for OT (StimuScent®, Dos Medical, Sense Trading BV, Groningen, The Netherlands)...EO's sensory properties/bioactivity were also related to the in silico physicochemical/pharmacokinetic properties of the main EO components. Our results provide new insights into a more targeted EO application for OT."

Journal • Neuroblastoma • Oncology • Solid Tumor

Pharmacokinetic/Pharmacodynamic Parameters of NNG-DEPO (Stimus) With Aranesp® (Amgen) in Treatment of Anemia in CKD Patients on Dialysis (clinicaltrials.gov) - P1 | N=43 | Completed | Sponsor: Nanogen Pharmaceutical Biotechnology Joint Stock Company | Active, not recruiting ➔ Completed

Trial completion • Anemia • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease

A Study to Compare Efficacy and Safety of Nanogen's Darbepoetin Alfa With Aranesp® (Amgen) in the Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis (CKD) (clinicaltrials.gov) - P3 | N=214 | Completed | Sponsor: Nanogen Pharmaceutical Biotechnology Joint Stock Company | Active, not recruiting ➔ Completed

Trial completion • Anemia • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease